Moreover, as plasma GLP-1 levels were found to be decreased in type 2 diabetic patients compared to control non-diabetic subjects [41], the development of novel anti-diabetic interventions that enhance endogenous incretin secretion appears an attractive therapeutic strategy. Here, GCG is linked to type 2 diabetes mellitus.